The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate corneal confocal microscopic findings, ocular
signs and symptoms in patients on treatment with the preserved prostaglandin analogue
latanoprost 0.005% eye drops (Xalatan®) and after the switch to preservative-free
prostaglandin analog tafluprost 0.0015% eye drops (Taflotan®). Patients who have been using
latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion
criteria including the specified ocular symptoms and signs, will switch from latanoprost
0.005% eye drops to the assigned preservative-free tafluprost 0.0015% eye drops for twelve
(12) months.
Phase:
Phase 4
Details
Lead Sponsor:
FinnMedi Oy
Collaborators:
Tampere University The Laboratory and Pharmacy Public Utility of the Pirkanmaa Hospital District University of Tampere